They lost more than half of the group that reviews malignant heme products. They've seen 473 departures of medical reviewers, voluntary departures, on top of about 600 RIFs. That's more than 20% at [the] center. So you're seeing a hollowing out of the scientific staff at the fda, and that's starting to impact early reviews. (08:07)
CLAIM
Asserts that more than 20% of the staff at the center have departed.
This is an excerpt from a raw transcript. The assertions have not been audited or verified. Tap the video to view the source footage and understand the context.
